Proteomics

Dataset Information

0

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in MLL1-rearranged AML cells

ABSTRACT: We treated MLL1-rearranged AML MOLM13 cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for different time intervals (up to 48 hours) to measure the time-dependent changes to the AML proteome

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Acute Leukemia

SUBMITTER: Antrix Jain  

LAB HEAD: Warren Fiskus

PROVIDER: PXD047965 | Pride | 2025-05-26

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
50262_1_MSProtCore_846_TMT10_Plex1_prof_250ng_F01.pepXML Pepxml
50262_1_MSProtCore_846_TMT10_Plex1_prof_250ng_F01.raw Raw
50262_1_MSProtCore_846_TMT10_Plex1_prof_250ng_F02.pepXML Pepxml
50262_1_MSProtCore_846_TMT10_Plex1_prof_250ng_F02.raw Raw
50262_1_MSProtCore_846_TMT10_Plex1_prof_250ng_F03.pepXML Pepxml
Items per page:
1 - 5 of 50
altmetric image

Publications

<h4>Abstract</h4>BRG1 (SMARCA4) and BRM (SMARCA2) are the mutually exclusive core ATPases of the chromatin remodeling BAF (BRG1/BRM-associated factor) complexes. They enable transcription factors/cofactors to access enhancers/promoter and modulate gene expressions responsible for cell growth and differentiation of acute myeloid leukemia (AML) stem/progenitor cells. In AML with MLL1 rearrangement (MLL1r) or mutant NPM1 (mtNPM1), although menin inhibitor (MI) treatment induces clinical remissions,  ...[more]

Similar Datasets

Proteomics Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells
2025-05-06 | PXD047967 | Pride
Proteomics Project title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells
2025-04-28 | PXD055994 | Pride
Proteomics Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
2025-04-28 | PXD053548 | Pride
Proteomics IKAROS and MENIN are Functionally Cooperative Therapeutic Targets in Acute Myeloid Leukemia
2022-03-11 | PXD025271 | Pride
Proteomics IKAROS and MENIN are Functionally Cooperative Therapeutic Targets in Acute Myeloid Leukemia
2022-03-11 | PXD025272 | Pride
Transcriptomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (Bulk RNA-Seq)
2024-03-01 | GSE252934 | GEO
Genomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (Bulk ATAC-Seq)
2024-03-01 | GSE252933 | GEO
Genomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (ChIP-Seq)
2024-03-01 | GSE252935 | GEO
Transcriptomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scRNA-Seq)
2024-03-01 | GSE252937 | GEO
Genomics BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scATAC-Seq)
2024-03-01 | GSE252936 | GEO